注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
江蘇瑞科生物技術股份有限公司是一家從事疫苗研發的中國公司。該公司擁有一系列臨床和臨床前階段的疫苗,人乳頭瘤病毒(HPV)疫苗管線包括重組HPV九價候選疫苗REC603,重組HPV二價候選疫苗REC601及REC602,重組HPV四價疫苗REC604a以及重組HPV九價疫苗REC604b。該公司還參與新冠病毒疫苗的研發。該公司主要在國內市場銷售其產品。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Feng Gao | 61 | 2021 | Independent Non-Executive Director |
Hongbin Zhou | 50 | 2020 | Non-Executive Director |
Houwei Hu | - | 2023 | Non-Executive Director |
Weiwei Qiao | 36 | 2021 | Chairman of the Supervisory Board |
Jiaxin Zhang | - | 2023 | Non-Executive Director |
Ming Fai Yuen | 73 | 2021 | Independent Non-Executive Director |
Guodong Liang | 71 | 2021 | Independent Non-Executive Director |
Lijun Xia | 47 | 2021 | Independent Non-Executive Director |
Jianping Chen | 46 | 2019 | Vice GM & Executive Director |
Kunxue Hong | 59 | 2021 | Chief Scientist & Non-Executive Director |
Bu Li | 47 | 2021 | Vice GM & Executive Director |
Qingqing Chen | 41 | 2021 | Vice GM, CFO, Secretary & Executive Director |
Yong Liu | 51 | 2011 | Founder, CEO, GM & Chairman of the Board |
Feizhou Wang | 57 | 2022 | Supervisor |
Ranting Qian | 48 | 2021 | Supervisor |
Ping Liu | 45 | 2022 | Employee Representative Supervisor |
Ruwei Wang | - | 2024 | Non-Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核